Funding Rounds
MinervaX

MinervaX Series C (2023, $57M)

MinervaX

Developer of prophylactic vaccine against Group B Streptococcus.

View Company Profile

GET THE TOP 10 COMPANIES OF THE WEEK IN YOUR EMAIL, EVERY TUESDAY.

OR DOWNLOAD OUR DATABASE OF 17,000 COMPANIES →

Summary

Stage: Series C

Raised Amount: $57.28M

Raised Date: 2023-11-01

Investors